Tenofovir disoproxil-based pill regains its position as first choice for PrEP in the US
Cabotegravir long-acting PrEP out of reach for upper middle-income nations
Non-communicable diseases and mental illness make up the majority of treatment costs for people living with HIV in Denmark
Key population-led services now account for the majority of Thai PrEP users
Giving antibodies to prevent vertical transmission in Africa would be cost-effective or even save money, study finds
Second-line treatment nearly nine times more expensive than first-line in upper-middle income countries
Injectable PrEP can only cost a little more than oral PrEP if it is to be cost-effective, South African study finds
Just six injections a year can prevent HIV: here’s what it will take for the world to afford them
ViiV Healthcare to allow 90 countries to access generic versions of HIV prevention shot
